vs
Side-by-side financial comparison of Apyx Medical Corp (APYX) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Apyx Medical Corp is the larger business by last-quarter revenue ($19.2M vs $13.3M, roughly 1.4× Laird Superfood, Inc.). Apyx Medical Corp runs the higher net margin — -6.8% vs -13.2%, a 6.4% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 15.0%). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 16.1%).
Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
APYX vs LSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $13.3M |
| Net Profit | $-1.3M | $-1.8M |
| Gross Margin | 62.6% | 34.1% |
| Operating Margin | 0.1% | -13.5% |
| Net Margin | -6.8% | -13.2% |
| Revenue YoY | 34.7% | 15.0% |
| Net Profit YoY | 71.9% | -341.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $13.3M | ||
| Q3 25 | $12.9M | $12.9M | ||
| Q2 25 | $11.4M | $12.0M | ||
| Q1 25 | $9.4M | $11.7M | ||
| Q4 24 | $14.2M | $11.6M | ||
| Q3 24 | $11.5M | $11.8M | ||
| Q2 24 | $12.1M | $10.0M | ||
| Q1 24 | $10.2M | $9.9M |
| Q4 25 | $-1.3M | $-1.8M | ||
| Q3 25 | $-2.0M | $-975.1K | ||
| Q2 25 | $-3.8M | $-362.2K | ||
| Q1 25 | $-4.2M | $-156.2K | ||
| Q4 24 | $-4.6M | $-398.4K | ||
| Q3 24 | $-4.7M | $-166.1K | ||
| Q2 24 | $-6.6M | $-239.1K | ||
| Q1 24 | $-7.6M | $-1.0M |
| Q4 25 | 62.6% | 34.1% | ||
| Q3 25 | 64.4% | 36.5% | ||
| Q2 25 | 62.3% | 39.9% | ||
| Q1 25 | 60.1% | 41.9% | ||
| Q4 24 | 63.0% | 38.6% | ||
| Q3 24 | 60.5% | 43.0% | ||
| Q2 24 | 61.7% | 41.8% | ||
| Q1 24 | 58.1% | 40.0% |
| Q4 25 | 0.1% | -13.5% | ||
| Q3 25 | -6.5% | -7.7% | ||
| Q2 25 | -22.6% | -3.3% | ||
| Q1 25 | -32.4% | -1.9% | ||
| Q4 24 | -21.4% | -4.1% | ||
| Q3 24 | -31.6% | -2.3% | ||
| Q2 24 | -45.7% | -3.4% | ||
| Q1 24 | -64.6% | -11.0% |
| Q4 25 | -6.8% | -13.2% | ||
| Q3 25 | -15.4% | -7.6% | ||
| Q2 25 | -33.2% | -3.0% | ||
| Q1 25 | -44.0% | -1.3% | ||
| Q4 24 | -32.5% | -3.4% | ||
| Q3 24 | -40.9% | -1.4% | ||
| Q2 24 | -54.0% | -2.4% | ||
| Q1 24 | -74.0% | -10.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.19 | — | ||
| Q1 24 | $-0.22 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $5.1M |
| Total DebtLower is stronger | $37.5M | — |
| Stockholders' EquityBook value | $14.5M | $11.5M |
| Total Assets | $66.8M | $19.2M |
| Debt / EquityLower = less leverage | 2.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $5.1M | ||
| Q3 25 | $25.1M | $5.1M | ||
| Q2 25 | $29.3M | $3.9M | ||
| Q1 25 | $31.0M | $7.0M | ||
| Q4 24 | $31.7M | $8.3M | ||
| Q3 24 | $28.0M | $7.9M | ||
| Q2 24 | $32.7M | $7.6M | ||
| Q1 24 | $37.3M | $7.1M |
| Q4 25 | $37.5M | — | ||
| Q3 25 | $37.5M | — | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $14.5M | $11.5M | ||
| Q3 25 | $5.8M | $12.8M | ||
| Q2 25 | $7.3M | $13.4M | ||
| Q1 25 | $10.5M | $13.3M | ||
| Q4 24 | $14.2M | $13.2M | ||
| Q3 24 | $11.0M | $13.1M | ||
| Q2 24 | $14.7M | $12.6M | ||
| Q1 24 | $20.3M | $12.7M |
| Q4 25 | $66.8M | $19.2M | ||
| Q3 25 | $57.4M | $18.9M | ||
| Q2 25 | $58.2M | $20.4M | ||
| Q1 25 | $60.2M | $21.5M | ||
| Q4 24 | $64.8M | $19.3M | ||
| Q3 24 | $60.7M | $18.8M | ||
| Q2 24 | $65.4M | $18.0M | ||
| Q1 24 | $70.7M | $17.6M |
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | — | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.5M | $68.4K |
| Free Cash FlowOCF − Capex | $-2.8M | — |
| FCF MarginFCF / Revenue | -14.6% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.5M | $68.4K | ||
| Q3 25 | $-3.5M | $1.2M | ||
| Q2 25 | $-1.2M | $-2.8M | ||
| Q1 25 | $-702.0K | $-1.3M | ||
| Q4 24 | $-2.9M | $339.2K | ||
| Q3 24 | $-4.4M | $305.8K | ||
| Q2 24 | $-4.3M | $642.7K | ||
| Q1 24 | $-6.3M | $-422.3K |
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-4.1M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-757.0K | — | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $-4.6M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $-6.4M | — |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -31.5% | — | ||
| Q2 25 | -13.2% | — | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | -22.4% | — | ||
| Q3 24 | -40.0% | — | ||
| Q2 24 | -38.0% | — | ||
| Q1 24 | -62.2% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 0.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APYX
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
